The supply has verified THC’s product pathway from manufacturer through to patient under federal authorised prescriber and special access schemes, as well as relevant state regulations.
THC is currently importing four products from Endoca’s range: Endoca’s CBD oil in 3% and 15% concentrations; and Endoca’s unique CBD-plus-CBDa oils also in 3% and 15% concentrations.
THC is also preparing to change its company name to THC Global Group Limited, with a resolution to be put forward at the company’s annual general meeting on November 15.
THC chief executive officer Ken Charteris said: “The ability to secure supply of high-quality GMP-certified medicinal cannabis products to domestic patients is a key bridge to implementation of THC Global’s ‘Farm-to-Pharma’ model.
“We continue to build out our domestic infrastructure in Australia under our Farm-to-Pharma model – research, growing, manufacture and supply.”
THC is building patient and prescriber awareness including sponsoring educational events to highlight the benefits of treatment with medicinal cannabis and the pathways to access the product in Australia.
As awareness increases within the domestic market, THC expects to see corresponding increases in revenue-generating product sales.
The company has also made available documentation for doctors and other prescribers to assist in prescribing Endoca’s products in Australia under the authorised prescriber and special access schemes.